Effect of the Pleiotropic Drug CNB-001 on Tissue Plasminogen Activator (tPA) Protease Activity in vitro: Support for Combination Therapy to Treat Acute Ischemic Stroke
Current state-of-the-art acute ischemic stroke clinical trials are designed to study neuroprotectants when administered following thrombolysis; tissue plasminogen activator (tPA) is administered to patients within 3–4.5 hours of an ischemic event. Thus, in order to develop a novel neuroprotectant an...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215513/ |